Getting our priorities straight

A novel framework for stakeholder-informed prioritization of cancer genomics research

Laura C. Esmail, Josh Roth, Sneha Rangarao, Josh J. Carlson, Rahber Thariani, Scott D. Ramsey, David L. Veenstra, Patricia Deverka

Research output: Contribution to journalArticle

Abstract

Purpose:Prioritization of translational research on genomic tests is critically important given the rapid pace of innovation in genomics. The goal of this study was to evaluate a stakeholder-informed priority-setting framework in cancer genomics.Methods:An external stakeholder advisory group including patients/consumers, payers, clinicians, and test developers used a modified Delphi approach to prioritize six candidate cancer genomic technologies during a 1-day meeting. Nine qualitative priority-setting criteria were considered. We used a directed, qualitative content-analysis approach to investigate the themes of the meeting discussion.Results:Stakeholders primarily discussed six of the original nine criteria: clinical benefits, population health impacts, economic impacts, analytical and clinical validity, clinical trial implementation and feasibility, and market factors. Several new priority-setting criteria were identified from the workshop transcript, including "patient-reported outcomes," "clinical trial ethics," and "trial recruitment." The new criteria were incorporated with prespecified criteria to develop a novel priority-setting framework.Conclusion:This study highlights key criteria that stakeholders can consider when prioritizing comparative effectiveness research for cancer genomic applications. Applying an explicit priority-setting framework to inform investment in comparative effectiveness research can help to ensure that critical factors are weighed when deciding between many potential research questions and trial designs.

Original languageEnglish (US)
Pages (from-to)115-122
Number of pages8
JournalGenetics in Medicine
Volume15
Issue number2
DOIs
StatePublished - Feb 1 2013
Externally publishedYes

Fingerprint

Genomics
Comparative Effectiveness Research
Research
Clinical Ethics
Clinical Trials
Neoplasms
Translational Medical Research
Insurance Benefits
Economics
Technology
Education
Population

Keywords

  • comparative effectiveness
  • framework
  • genomic
  • priority setting
  • qualitative
  • stakeholder

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Esmail, L. C., Roth, J., Rangarao, S., Carlson, J. J., Thariani, R., Ramsey, S. D., ... Deverka, P. (2013). Getting our priorities straight: A novel framework for stakeholder-informed prioritization of cancer genomics research. Genetics in Medicine, 15(2), 115-122. https://doi.org/10.1038/gim.2012.103

Getting our priorities straight : A novel framework for stakeholder-informed prioritization of cancer genomics research. / Esmail, Laura C.; Roth, Josh; Rangarao, Sneha; Carlson, Josh J.; Thariani, Rahber; Ramsey, Scott D.; Veenstra, David L.; Deverka, Patricia.

In: Genetics in Medicine, Vol. 15, No. 2, 01.02.2013, p. 115-122.

Research output: Contribution to journalArticle

Esmail, LC, Roth, J, Rangarao, S, Carlson, JJ, Thariani, R, Ramsey, SD, Veenstra, DL & Deverka, P 2013, 'Getting our priorities straight: A novel framework for stakeholder-informed prioritization of cancer genomics research', Genetics in Medicine, vol. 15, no. 2, pp. 115-122. https://doi.org/10.1038/gim.2012.103
Esmail, Laura C. ; Roth, Josh ; Rangarao, Sneha ; Carlson, Josh J. ; Thariani, Rahber ; Ramsey, Scott D. ; Veenstra, David L. ; Deverka, Patricia. / Getting our priorities straight : A novel framework for stakeholder-informed prioritization of cancer genomics research. In: Genetics in Medicine. 2013 ; Vol. 15, No. 2. pp. 115-122.
@article{ff54e149f7894aa8b3efcd35591a5dfd,
title = "Getting our priorities straight: A novel framework for stakeholder-informed prioritization of cancer genomics research",
abstract = "Purpose:Prioritization of translational research on genomic tests is critically important given the rapid pace of innovation in genomics. The goal of this study was to evaluate a stakeholder-informed priority-setting framework in cancer genomics.Methods:An external stakeholder advisory group including patients/consumers, payers, clinicians, and test developers used a modified Delphi approach to prioritize six candidate cancer genomic technologies during a 1-day meeting. Nine qualitative priority-setting criteria were considered. We used a directed, qualitative content-analysis approach to investigate the themes of the meeting discussion.Results:Stakeholders primarily discussed six of the original nine criteria: clinical benefits, population health impacts, economic impacts, analytical and clinical validity, clinical trial implementation and feasibility, and market factors. Several new priority-setting criteria were identified from the workshop transcript, including {"}patient-reported outcomes,{"} {"}clinical trial ethics,{"} and {"}trial recruitment.{"} The new criteria were incorporated with prespecified criteria to develop a novel priority-setting framework.Conclusion:This study highlights key criteria that stakeholders can consider when prioritizing comparative effectiveness research for cancer genomic applications. Applying an explicit priority-setting framework to inform investment in comparative effectiveness research can help to ensure that critical factors are weighed when deciding between many potential research questions and trial designs.",
keywords = "comparative effectiveness, framework, genomic, priority setting, qualitative, stakeholder",
author = "Esmail, {Laura C.} and Josh Roth and Sneha Rangarao and Carlson, {Josh J.} and Rahber Thariani and Ramsey, {Scott D.} and Veenstra, {David L.} and Patricia Deverka",
year = "2013",
month = "2",
day = "1",
doi = "10.1038/gim.2012.103",
language = "English (US)",
volume = "15",
pages = "115--122",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Getting our priorities straight

T2 - A novel framework for stakeholder-informed prioritization of cancer genomics research

AU - Esmail, Laura C.

AU - Roth, Josh

AU - Rangarao, Sneha

AU - Carlson, Josh J.

AU - Thariani, Rahber

AU - Ramsey, Scott D.

AU - Veenstra, David L.

AU - Deverka, Patricia

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Purpose:Prioritization of translational research on genomic tests is critically important given the rapid pace of innovation in genomics. The goal of this study was to evaluate a stakeholder-informed priority-setting framework in cancer genomics.Methods:An external stakeholder advisory group including patients/consumers, payers, clinicians, and test developers used a modified Delphi approach to prioritize six candidate cancer genomic technologies during a 1-day meeting. Nine qualitative priority-setting criteria were considered. We used a directed, qualitative content-analysis approach to investigate the themes of the meeting discussion.Results:Stakeholders primarily discussed six of the original nine criteria: clinical benefits, population health impacts, economic impacts, analytical and clinical validity, clinical trial implementation and feasibility, and market factors. Several new priority-setting criteria were identified from the workshop transcript, including "patient-reported outcomes," "clinical trial ethics," and "trial recruitment." The new criteria were incorporated with prespecified criteria to develop a novel priority-setting framework.Conclusion:This study highlights key criteria that stakeholders can consider when prioritizing comparative effectiveness research for cancer genomic applications. Applying an explicit priority-setting framework to inform investment in comparative effectiveness research can help to ensure that critical factors are weighed when deciding between many potential research questions and trial designs.

AB - Purpose:Prioritization of translational research on genomic tests is critically important given the rapid pace of innovation in genomics. The goal of this study was to evaluate a stakeholder-informed priority-setting framework in cancer genomics.Methods:An external stakeholder advisory group including patients/consumers, payers, clinicians, and test developers used a modified Delphi approach to prioritize six candidate cancer genomic technologies during a 1-day meeting. Nine qualitative priority-setting criteria were considered. We used a directed, qualitative content-analysis approach to investigate the themes of the meeting discussion.Results:Stakeholders primarily discussed six of the original nine criteria: clinical benefits, population health impacts, economic impacts, analytical and clinical validity, clinical trial implementation and feasibility, and market factors. Several new priority-setting criteria were identified from the workshop transcript, including "patient-reported outcomes," "clinical trial ethics," and "trial recruitment." The new criteria were incorporated with prespecified criteria to develop a novel priority-setting framework.Conclusion:This study highlights key criteria that stakeholders can consider when prioritizing comparative effectiveness research for cancer genomic applications. Applying an explicit priority-setting framework to inform investment in comparative effectiveness research can help to ensure that critical factors are weighed when deciding between many potential research questions and trial designs.

KW - comparative effectiveness

KW - framework

KW - genomic

KW - priority setting

KW - qualitative

KW - stakeholder

UR - http://www.scopus.com/inward/record.url?scp=84873555093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873555093&partnerID=8YFLogxK

U2 - 10.1038/gim.2012.103

DO - 10.1038/gim.2012.103

M3 - Article

VL - 15

SP - 115

EP - 122

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 2

ER -